The clinical impact of neuropsychiatric manifestations in early systemic lupus erythematosus.

Sjögren's Syndrome Clinic, National Institute of Dental and Craniofacial Research, Gene Therapy and Therapeutics Branch, National Institutes of Health, Bethesda, MD 20892, USA.
Nature Clinical Practice Rheumatology (Impact Factor: 5.85). 09/2007; 3(8):428-9. DOI: 10.1038/ncprheum0553
Source: PubMed
1 Read
  • [Show abstract] [Hide abstract]
    ABSTRACT: In order to better understand the clinical manifestation of systemic lupus erythematosus (SLE) with intracranial hypertension syndrome (IHS), we analyzed the clinical features and treatment of a typical SLE patient with IHS. SLE is one of the most unpredictable autoimmune diseases involving multiple organ systems that is defined clinically and associated with antibodies directed against cell nuclei. IHS is an uncommon manifestation of neuropsychiatric SLE (NPSLE) and is characterized by an elevated intracranial pressure, papilledema, and headache with occasional abducens nerve paresis, absence of a space-occupying lesion or ventricular enlargement, and normal cerebrospinal fluid chemical and hematological constituents. IHS has been reported in a few sporadic cases in patients with SLE worldwide, but rarely has been reported in China. In this study, a 34-year-old female SLE patient with IHS was reported and pertinent literature reviewed. The clinical presentation, image logical features, and investigatory findings were discussed.
    Journal of Huazhong University of Science and Technology 03/2009; 29(1):107-11. DOI:10.1007/s11596-009-0123-3 · 0.83 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Systemic lupus erythematosus (SLE) is one of the best-studied autoimmune diseases from the point of view of understanding how the acquisition of epigenetic abnormalities associates with the development of autoimmunity. The disease, which primarily affects women, is characterized by the formation of autoantibodies to nuclear antigens and immune-complex deposition in tissues such as the skin and kidney. It has been proposed that SLE arises in genetically predisposed individuals when exposed to one or more environmental triggers. Specifically, environmentally induced epigenetic changes, and in particular altered DNA methylation changes, have been described as being associated with lupus. In this article, we discuss the implications of changes in DNA methylation and other epigenetic alterations with respect to SLE, and how our knowledge of the epigenetic targets in SLE can contribute not only to a better understanding disease pathogenesis, but also to the design of novel and more specific pharmaceutical compounds.
    The Epigenetics of Autoimmune Diseases, 04/2009: pages 229 - 246; , ISBN: 9780470743553